<DOC>
	<DOCNO>NCT00581620</DOCNO>
	<brief_summary>To determine immunogenicity heptavalent CRM197 pneumococcal conjugate child immunodeficiency condition . To evaluate tolerability PrevenarÂ® population .</brief_summary>
	<brief_title>Study Evaluating Prevenar Immunogenicity High Risk Children</brief_title>
	<detailed_description>This study require 24 month complete . Each child participate period time accord age 1st dose vaccination : infant 6 month age evaluate 5 month ; infant 7 11 month evaluate 3 month ; child 12 month 9 year age evaluate 2 month</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Children 2 month 9 year old . Children HIV+ ; Sickle Cell disease ; Neprotic symdrome ; Chronic pulmonary disease No history seizure</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>pneumococcus conjugate vaccine</keyword>
</DOC>